place

Massachusetts Correctional Institution – Framingham

1877 establishments in MassachusettsBuildings and structures in Framingham, MassachusettsPrisons in MassachusettsWomen's prisons in the United States

Massachusetts Correctional Institution – Framingham (MCI-Framingham) is the Massachusetts Department of Correction's institution for female offenders. It is located in Framingham, Massachusetts, a city located midway between Worcester and Boston. The prison was once known as "Framingham State Prison". However, MCI-Framingham is its official name and is favored. As of May 2022 there are approximately 190 inmates in general population beds.

Excerpt from the Wikipedia article Massachusetts Correctional Institution – Framingham (License: CC BY-SA 3.0, Authors).

Massachusetts Correctional Institution – Framingham
Loring Drive, Framingham

Geographical coordinates (GPS) Address External links Nearby Places
placeShow on map

Wikipedia: Massachusetts Correctional Institution – FraminghamContinue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 42.267038888889 ° E -71.407005555556 °
placeShow on map

Address

Massachusetts Correctional Institution Framingham

Loring Drive 99
01701 Framingham
Massachusetts, United States
mapOpen on Google Maps

linkWikiData (Q14715701)
linkOpenStreetMap (947062471)

Share experience

Nearby Places

New England Compounding Center meningitis outbreak
New England Compounding Center meningitis outbreak

A New England Compounding Center meningitis outbreak that began in September 2012 sickened 798 individuals and resulted in the deaths of more than 100 people. In September 2012, the Centers for Disease Control and Prevention, in collaboration with state and local health departments and the Food and Drug Administration (FDA), began investigating a multistate outbreak of fungal meningitis and other infections among patients who had received contaminated steroid injections from the New England Compounding Center (NECC) in Framingham, Massachusetts. The NECC was classified as a compounding pharmacy. The traditional role of compounding pharmacies is to make drugs prescribed by doctors for specific patients with needs that can't be met by commercially available drugs.In October 2012, an investigation of the NECC revealed the company had been in violation of its state license because it had been functioning as a drug manufacturer, producing drugs for broad use rather than filling individual prescriptions. In December 2012, federal prosecutors charged 14 former NECC employees, including president Barry Cadden and pharmacist Glenn Chin, with a host of criminal offenses. It alleged that from 2006 to 2012, NECC knowingly sent out drugs that were mislabeled and unsanitary or contaminated. In a congressional hearing the FDA Commissioner was asked why regulators at the FDA and the Massachusetts Board of Pharmacy did not take action against the pharmacy years earlier. The legislators were told that the agency was obligated to defer to Massachusetts authorities, who had more direct oversight over pharmacies. The FDA Commissioner also stated, "In light of growing evidence of threats to the public health, the administration urges Congress to strengthen standards for non-traditional compounding." The Drug Quality and Security Act (H.R. 3204), a bill to grant the FDA more authority to regulate and monitor the manufacturing of compounding drugs, was passed by the Senate on November 27, 2013. The incident resulted in numerous lawsuits against NECC. In May 2015, a $200 million settlement plan was approved that set aside funds for victims of the outbreak and their families.